
    
      This is a multi-center, randomized, double-blind study designed to investigate the safety,
      pharmacokinetic (PK) profile and efficacy of a single injection of COVI-AMG in outpatient
      adults with mild COVID-19 symptoms. Subjects will be followed for approximately 70 days post
      dosing.
    
  